Shopping Cart
- Remove All
Your shopping cart is currently empty
Enzaplatovir
Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
Catalog No. T27271Cas No. 1323077-89-9
Select Batch
Purity:99.72%
Contact us for more batch information
Enzaplatovir
Catalog No. T27271Alias BTA-C585, BTAC585, BTA-585, BTA585, BTA 585Cas No. 1323077-89-9
Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $215 | In Stock | |
| 5 mg | $538 | In Stock | |
| 10 mg | $868 | In Stock | |
| 25 mg | $1,520 | In Stock | |
| 50 mg | $1,980 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $589 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Enzaplatovir"
Ribavirin
Cited
Tribavirin, RTCA, NSC-163039, ICN-1229
T068436791-04-5
Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.
- $39
Size
QTY
CitedRoflumilast Cited
BYK 20869, BY 217, B9302-107, APTA 2217
T1024162401-32-3
Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.
Inquiry
CitedAmentoflavone
Cited
Didemethyl-ginkgetin, Amenthoflavone, 3',8''-Biapigenin
T34171617-53-4
Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.
- $30
Size
QTY
CitedZiresovir
RO-0529, AK0529
T134011422500-60-4In house
Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.
- $173
Size
QTY
BTA-9881
MEDI-564, BTA9881, BTA 9881, AZD-9639, AZD9639
T269141646857-24-0In house
BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.
- $80
Size
QTY
Presatovir
GS-5806
TQ00851353625-73-6
Presatovir (GS-5806) (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM).
- $58
Size
QTY
4-Methoxycinnamaldehyde
p-Methoxycinnamaldehyde
TN30481963-36-6
4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde) is an active ingredient of Agastache rugosa.4-Methoxycinnamaldehyde has cytoprotective activity against respiratory syncytial virus (RSV) in human laryngeal carcinoma cell lines, and helps to control disease induced by RSV infection, with an IC50 of approximately 0.055 μg/mL. The IC50 was about 0.055 μg/mL.
- $39
Size
QTY
Rilematovir
JNJ-678, JNJ-53718678
T156211383450-81-4
Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.
- $40
Size
QTY
KIN101
3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene
T11760610753-87-2
KIN101 (3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene), an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has antiviral activity against RNA viruses, HCV, and RSV.
- $29
Size
QTY
Ac-CoA Synthase Inhibitor1
ACSS2 inhibitor
T4380508186-14-9
Ac-CoA Synthase Inhibitor1 (ACSS2 inhibitor) is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2).
- $41
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections. |
| Alias | BTA-C585, BTAC585, BTA-585, BTA585, BTA 585 |
| Molecular Weight | 377.4 |
| Formula | C20H19N5O3 |
| Cas No. | 1323077-89-9 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (397.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Enzaplatovir | purchase Enzaplatovir | Enzaplatovir cost | order Enzaplatovir | Enzaplatovir chemical structure | Enzaplatovir formula | Enzaplatovir molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.